Uveal Melanoma: Dual T Cell Drugs Hit 70% Two-Year Survival Where Checkpoint Drugs Failed
· techtimes.com · popularity 20/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at techtimes.com →
Summary
Uveal melanoma treatment advanced in 2026 when Immunocore's brenetafusp plus tebentafusp combination kept 70% of patients alive at two years, in a cancer where median survival was 12 months and checkpoint immunotherapy had consistently failed. Phase 1/2 data at SITC 2026 also showed 89% molecular response rates, suggesting a durable shift in solid tumor immunotherapy.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 5.